How much did Neuropace achieve in EBIT for the current year?
In the current year, Neuropace has achieved an EBIT of -24.43 M USD.
Neuropace EBIT 2024
Neuropace EBIT
-24.43 M USD
Ticker
NPCE
ISIN
US6412881053
In 2024, Neuropace's EBIT was -24.43 M USD, a -10.08% increase from the -27.17 M USD EBIT recorded in the previous year.
The Neuropace EBIT history
| YEAR | EBIT (undefined USD) |
|---|---|
| 2029e | - |
| 2028e | - |
| 2027e | - |
| 2026e | - |
| 2025e | - |
| 2024e | - |
| 2023 | - |
| 2022 | - |
| 2021 | - |
| 2020 | - |
| 2019 | - |
Neuropace Revenue, EBIT, Net Income US6412881053 ·
3 years
5 years
10 years
25 Years
Max
Revenue
EBIT
Net Income
Details
Revenue, EBIT and Profit
ⓘUnderstanding Revenue, EBIT, and Income
Gain insights into Neuropace, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Neuropace from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Neuropace’s net earnings, an ultimate measure of its financial health and profitability.
Yearly Analysis and Comparisons
Observe the yearly bars to understand the annual performance and growth of Neuropace. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.
Utilizing Expectations for Investment
The expected values for the forthcoming years offer investors a glimpse into Neuropace’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.
Investment Insights
Leveraging the comparison between Revenue and EBIT helps in assessing Neuropace’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Neuropace’s growth potential.
Neuropace Revenue, EBIT and net profit per share
| Date | Neuropace Revenue | Neuropace EBIT | Neuropace Net Income |
|---|---|---|---|
| 2029e | 241.29 M undefined | 0 undefined | 22.53 M undefined |
| 2028e | 211.08 M undefined | 0 undefined | 8.22 M undefined |
| 2027e | 155.26 M undefined | 0 undefined | -8.53 M undefined |
| 2026e | 111.34 M undefined | -14.45 M undefined | -18.78 M undefined |
| 2025e | 92.75 M undefined | -23.02 M undefined | -27.62 M undefined |
| 2024e | 80.75 M undefined | -24.43 M undefined | -30.66 M undefined |
| 2023 | 65.42 M undefined | -27.17 M undefined | -32.96 M undefined |
| 2022 | 45.52 M undefined | -40.79 M undefined | -47.08 M undefined |
| 2021 | 45.18 M undefined | -23.74 M undefined | -36.08 M undefined |
| 2020 | 41.14 M undefined | -13.05 M undefined | -24.05 M undefined |
| 2019 | 36.97 M undefined | -22.03 M undefined | -29.97 M undefined |
| Revenue | EBIT | Net Income | |
|---|---|---|---|
| 2019 | 36.97 M USD | -22.03 M USD | -29.97 M USD |
| 2020 | 41.14 M USD | -13.05 M USD | -24.05 M USD |
| 2021 | 45.18 M USD | -23.74 M USD | -36.08 M USD |
| 2022 | 45.52 M USD | -40.79 M USD | -47.08 M USD |
| 2023 | 65.42 M USD | -27.17 M USD | -32.96 M USD |
| 2024e | 80.75 M USD | -24.43 M USD | -30.66 M USD |
| 2025e | 92.75 M USD | -23.02 M USD | -27.62 M USD |
| 2026e | 111.34 M USD | -14.45 M USD | -18.78 M USD |
| 2027e | 155.26 M USD | 0 USD | -8.53 M USD |
| 2028e | 211.08 M USD | 0 USD | 8.22 M USD |
| 2029e | 241.29 M USD | 0 USD | 22.53 M USD |
Neuropace stock margins US6412881053 ·
The Neuropace margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Neuropace. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Neuropace.
3 years
5 years
10 years
25 Years
Max
Gross margin
EBIT margin
Profit margin
Details
Margin
ⓘUnderstanding Gross Margin
The gross margin, expressed as a percentage, delineates the gross profit made from the Neuropace's sales revenue. A higher gross margin percentage indicates that the Neuropace retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.
EBIT Margin Analysis
EBIT margin represents the Neuropace's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.
Revenue Margin Insights
The revenue margin demonstrates the Neuropace's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Neuropace's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.
Interpreting Expectations
The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Neuropace. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.
Comparative Analysis
Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Neuropace's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.
Neuropace Margin History
| Neuropace Gross margin | Neuropace Profit margin | Neuropace EBIT margin | Neuropace Profit margin |
|---|---|---|---|
| 2029e | 73.56 % | 0 % | 9.34 % |
| 2028e | 73.56 % | 0 % | 3.89 % |
| 2027e | 73.56 % | 0 % | -5.49 % |
| 2026e | 73.56 % | -12.98 % | -16.86 % |
| 2025e | 73.56 % | -24.82 % | -29.78 % |
| 2024e | 73.56 % | -30.26 % | -37.97 % |
| 2023 | 73.56 % | -41.54 % | -50.38 % |
| 2022 | 71.38 % | -89.61 % | -103.43 % |
| 2021 | 74.02 % | -52.55 % | -79.86 % |
| 2020 | 73.58 % | -31.72 % | -58.46 % |
| 2019 | 71.57 % | -59.59 % | -81.07 % |
| Gross margin | EBIT margin | Profit margin | |
|---|---|---|---|
| 2019 | 71.57 % | -59.59 % | -81.07 % |
| 2020 | 73.58 % | -31.72 % | -58.46 % |
| 2021 | 74.02 % | -52.55 % | -79.86 % |
| 2022 | 71.38 % | -89.61 % | -103.43 % |
| 2023 | 73.56 % | -41.54 % | -50.38 % |
| 2024e | 73.56 % | -30.26 % | -37.97 % |
| 2025e | 73.56 % | -24.82 % | -29.78 % |
| 2026e | 73.56 % | -12.98 % | -16.86 % |
| 2027e | 73.56 % | 0 % | -5.49 % |
| 2028e | 73.56 % | 0 % | 3.89 % |
| 2029e | 73.56 % | 0 % | 9.34 % |
Neuropace Aktienanalyse
What does Neuropace do?
Neuropace Inc is a US-based company specializing in the development and manufacturing of medical devices. It is headquartered in Mountain View, California and has been operating since 2000. The company was founded as a spin-off from a study conducted by Dr. Martha Morrell at Stanford University, focusing on the treatment of epilepsy with implanted devices. Neuropace Inc's business model involves manufacturing and marketing medical devices for epilepsy treatment. These devices, known as neurostimulators, are implantable devices that send electrical impulses to the brain and can reduce epileptic seizures. The company has been involved in various areas of epilepsy treatment, including the development of devices for patients with pharmacoresistant focal epilepsies. These devices can be implanted in patients who do not respond to traditional treatments such as medications or surgeries. Neuropace Inc has also started focusing on the development of devices for epilepsy diagnosis. One of these devices is the ambulatory EEG monitor, which records brain activity and allows doctors to better detect epilepsy seizures. The company has launched a range of products to achieve its goal of enabling patients to have a better quality of life. The key product is the RNS neurostimulator, which is implanted in patients and continuously monitors brain activity using electrodes placed in the brain to monitor brain waves. When the neurostimulator detects unusual activity, it automatically sends impulses to the brain to prevent or reduce the occurrence of epileptic seizures. The benefit is that patients experience fewer seizures and can better organize and plan their daily lives. Neuropace Inc has a competitive position in the market with its products for treating pharmacoresistant focal epilepsies. The RNS neurostimulator is the only device approved by the US Food and Drug Administration FDA capable of reducing critical neurological outcomes in epilepsy. The company also has a strong presence in the field of epilepsy diagnosis, particularly with the ambulatory EEG monitor. Neuropace Inc has also formed strategic partnerships with other companies to bring its technologies to the market. The company has formed alliances with Medtronic, among others, for the marketing and distribution of the RNS neurostimulator. Through these partnerships, Neuropace Inc has expanded its reach in the market and strengthened its relationships with leading companies in the industry. In summary, Neuropace Inc is a company specializing in the development and manufacturing of medical devices for epilepsy treatment. The company has expanded its technologies to cover a broader range of epilepsy conditions and has achieved a high level of success with its products. With solid partnerships and a strong commitment to epilepsy treatment, Neuropace Inc is expected to continue leading the market for medical devices. Neuropace ist eines der beliebtesten Unternehmen auf Eulerpool.com.EBIT Details
Analyzing Neuropace's EBIT
Neuropace's Earnings Before Interest and Taxes (EBIT) represents the company's operating profit. It is calculated by deducting all operating expenses, including the cost of goods sold (COGS) and operating expenses, from the total revenue, but before accounting for interest and taxes. It provides insights into the company’s operational profitability, excluding the impacts of financing and tax structures.
Year-to-Year Comparison
A yearly comparison of Neuropace's EBIT can reveal trends in the company’s operational efficiency and profitability. An increase in EBIT over the years can indicate enhanced operational efficiency or growth in revenue, while a decrease might raise concerns about increased operating costs or declining sales.
Impact on Investments
Neuropace's EBIT is a significant metric for investors. A positive EBIT suggests that the company is generating enough revenue to cover its operating expenses, an essential aspect for assessing the company’s financial health and stability. Investors closely monitor EBIT to gauge the company’s profitability and potential for future growth.
Interpreting EBIT Fluctuations
Fluctuations in Neuropace’s EBIT can be due to variations in revenue, operating expenses, or both. An increasing EBIT indicates improved operational performance or increased sales, while a declining EBIT can signal rising operational costs or reduced revenue, prompting a need for strategic adjustments.
Frequently Asked Questions about Neuropace stock
What is EBIT?
EBIT stands for Earnings Before Interest and Taxes and refers to the profit before interest and taxes of a company Neuropace.
How has the EBIT of Neuropace developed in recent years?
The EBIT of Neuropace has increased by -10.085% decreased compared to the previous year.
What does EBIT mean for investors?
EBIT provides investors with insights into a company's profitability as it reflects the profit before interest expenses and taxes.
Why is EBIT an important indicator for investors?
Since EBIT provides a more direct insight into a company's profit than net income, it is an important indicator for investors to assess the profitability of a company.
Why do EBIT values fluctuate?
EBIT values can fluctuate as they are influenced by various factors, such as revenue, costs, and tax effects.
What role does tax burden play in EBIT?
Tax burdens have a direct impact on a company's EBIT, as they are deducted from the profit.
How is EBIT presented in the balance sheet of the company Neuropace?
The EBIT of Neuropace is listed in the income statement.
Can EBIT be used as a single indicator for evaluating a company?
EBIT is an important indicator for evaluating a company, but additional financial ratios should also be considered to get a comprehensive picture.
Why is EBIT not equal to net profit?
The net profit of a company includes taxes and interest, while EBIT represents the profit before interest and taxes.
How much dividend does Neuropace pay?
Over the past 12 months, Neuropace paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Neuropace is expected to pay a dividend of 0 USD.
What is the dividend yield of Neuropace?
The current dividend yield of Neuropace is .
When does Neuropace pay dividends?
Neuropace pays a quarterly dividend. This is distributed in the months of .
How secure is the dividend of Neuropace?
Neuropace paid dividends every year for the past 0 years.
What is the dividend of Neuropace?
For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.
In which sector is Neuropace located?
Neuropace is assigned to the 'Health' sector.
Wann musste ich die Aktien von Neuropace kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of Neuropace from 12/1/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 12/1/2024.
When did Neuropace pay the last dividend?
The last dividend was paid out on 12/1/2024.
What was the dividend of Neuropace in the year 2023?
In the year 2023, Neuropace distributed 0 USD as dividends.
In which currency does Neuropace pay out the dividend?
The dividends of Neuropace are distributed in USD.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
Andere Kennzahlen von Neuropace
Our stock analysis for Neuropace Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Neuropace Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.